Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Decline in measles vaccination is causing a preventable global resurgence of the disease
(NIH/National Institute of Allergy and Infectious Diseases) In 2000, measles was declared to be eliminated in the United States. Today, the US and many other countries are experiencing outbreaks of measles because of declines in measles vaccine coverage. Without renewed focus on vaccination efforts, the disease may rebound in full force, according to a commentary in NEJM by infectious diseases experts at the National Institute of Allergy and Infectious Diseases and Penn State University College of Medicine's Milton S. Hershey Medical Center.
Source: EurekAlert! - Infectious and Emerging Diseases - April 18, 2019 Category: Infectious Diseases Source Type: news
NIH awards will advance development of vaccines for sexually transmitted infections
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID) today announced awards to establish four Cooperative Research Centers (CRCs) focused on developing vaccines to prevent sexually transmitted infections (STIs). The grants, totaling $41.6 million over five years, will support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea and chlamydia. At the end of the program, each center is expected to identify at least one candidate vaccine ready for testing in clinical trials.
Source: EurekAlert! - Infectious and Emerging Diseases - May 9, 2019 Category: Infectious Diseases Source Type: news
NIAID announces two awards for multi-year studies of influenza immunity in children
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has announced two awards for the study of influenza immunity in children. The awards, which may total more than $64 million over seven years, will support studies led by Cincinnati Children's Hospital Medical Center and St. Jude Children's Research Hospital, examining how young children's immune systems respond over multiple years to their initial influenza infection and their first vaccination.
Source: EurekAlert! - Infectious and Emerging Diseases - May 22, 2019 Category: Infectious Diseases Source Type: news
NIH-supported study reveals a novel indicator of influenza immunity
(NIH/National Institute of Allergy and Infectious Diseases) A study of influenza virus transmission in Nicaraguan households reveals new insights into the type of immune responses that may be protective against influenza virus infection, report investigators. The findings could help scientists design more effective influenza vaccines and lead to the development of novel universal influenza vaccines. The research was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - June 3, 2019 Category: Infectious Diseases Source Type: news
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
(NIH/National Institute of Allergy and Infectious Diseases) Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - June 6, 2019 Category: Infectious Diseases Source Type: news
NIAID scientists develop 'mini-brain' model of human prion disease
(NIH/National Institute of Allergy and Infectious Diseases) Scientists have used human skin cells to create what they believe is the first cerebral organoid system, or 'mini-brain,' for studying sporadic Creutzfeldt-Jakob disease (CJD). CJD is a fatal neurodegenerative brain disease of humans believed to be caused by infectious prion protein. The researchers, from NIH's National Institute of Allergy and Infectious Diseases, hope the human organoid model will enable them to evaluate potential CJD therapeutics and provide greater detail about human prion disease subtypes.
Source: EurekAlert! - Infectious and Emerging Diseases - June 14, 2019 Category: Infectious Diseases Source Type: news
NIH awards contract for acute flaccid myelitis natural history study
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, has awarded the University of Alabama at Birmingham (UAB) approximately $10 million over five years to study acute flaccid myelitis (AFM), a rare but serious condition which causes muscle weakness and paralysis.
Source: EurekAlert! - Infectious and Emerging Diseases - July 23, 2019 Category: Infectious Diseases Source Type: news
Impact of combination HIV interventions on HIV incidence in hyperendemic fishing communities in Uganda: a prospective cohort study
Publication date: Available online 15 September 2019Source: The Lancet HIVAuthor(s): Joseph Kagaayi, Larry W Chang, Victor Ssempijja, M Kate Grabowski, Robert Ssekubugu, Gertrude Nakigozi, Godfrey Kigozi, David M Serwadda, Ronald H Gray, Fred Nalugoda, Nelson K Sew.ambo, Lisa Nelson, Lisa A Mills, Donna Kabatesi, Stella Alamo, Caitlin E Kennedy, Aaron A R Tobian, John S Santelli, Anna Mia Ekström, Helena NordenstedtSummaryBackgroundTargeting combination HIV interventions to locations and populations with high HIV burden is a global priority, but the impact of these strategies on HIV incidence is unclear. We assessed the i...
Source: The Lancet HIV - September 16, 2019 Category: Infectious Diseases Source Type: research
Study vaccine protects monkeys against four types of hemorrhagic fever viruses
(NIH/National Institute of Allergy and Infectious Diseases) Scientists funded by the National Institutes of Health have developed an investigational vaccine that protected cynomolgus macaques against four types of hemorrhagic fever viruses endemic to overlapping regions in Africa. The University of Texas Medical Branch in Galveston and Profectus BioSciences of New York are developing and testing the candidate quadrivalent VesiculoVax vaccine, with support from NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Redeemer's University in Nigeria.
Source: EurekAlert! - Infectious and Emerging Diseases - November 8, 2019 Category: Infectious Diseases Source Type: news
NIH renews funding for the Antibacterial Resistance Leadership Group
(NIH/National Institute of Allergy and Infectious Diseases) As antibiotic-resistant bacteria become more urgent threats worldwide, the National Institute of Allergy and Infectious Diseases will provide up to $102.5 million in renewed funding over seven years for the Antibacterial Resistance Leadership Group (ARLG). This global consortium of scientific experts leads a comprehensive clinical research network overseeing research on important scientific questions related to antibacterial resistance.
Source: EurekAlert! - Infectious and Emerging Diseases - December 13, 2019 Category: Infectious Diseases Source Type: news
Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda
Publication date: Available online 14 January 2020Source: The Lancet HIVAuthor(s): Oliver Ratmann, Joseph Kagaayi, Matthew Hall, Tanya Golubchick, Godfrey Kigozi, Xiaoyue Xi, Chris Wymant, Gertrude Nakigozi, Lucie Abeler-Dörner, David Bonsall, Astrid Gall, Anne Hoppe, Paul Kellam, Jeremiah Bazaale, Sarah Kalibbala, Oliver Laeyendecker, Justin Lessler, Fred Nalugoda, Larry W Chang, Tulio de OliveiraSummaryBackgroundInternational and global organisations advocate targeting interventions to areas of high HIV prevalence (ie, hotspots). To better understand the potential benefits of geo-targeted control, we assessed the extent...
Source: The Lancet HIV - January 15, 2020 Category: Infectious Diseases Source Type: research
NIAID officials discuss novel Coronavirus that recently emerged in China
(NIH/National Institute of Allergy and Infectious Diseases) The new cluster of viral pneumonia cases originating in Wuhan, China, marks the third time in 20 years that a member of the large family of coronaviruses (CoVs) has jumped from animals to humans and sparked an outbreak. In a new JAMA Viewpoint essay, Anthony S. Fauci, M.D., director of the NIH's National Institute of Allergy and Infectious Diseases (NIAID), looks back at two earlier novel CoV outbreaks that initially caused global havoc and describes steps needed to contain the current one.
Source: EurekAlert! - Infectious and Emerging Diseases - January 23, 2020 Category: Infectious Diseases Source Type: news
Experimental HIV vaccine regimen ineffective in preventing HIV
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine. This action was taken because an independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV. Importantly, the DSMB did not express any concern regarding participant safety.
Source: EurekAlert! - Infectious and Emerging Diseases - February 3, 2020 Category: Infectious Diseases Source Type: news
Recent advances in addressing tuberculosis give hope for future
(NIH/National Institute of Allergy and Infectious Diseases) In September 2018, the National Institute of Allergy and Infectious Diseases issued its Strategic Plan for Tuberculosis Research, which outlined research priorities to reduce and ultimately end the burden of tuberculosis (TB). Now, a new 'Perspective' in The Journal of Infectious Diseases by NIAID Director Anthony S. Fauci, M.D., and other Institute officials summarizes recent progress in improved TB diagnostics, therapeutic regimens and prevention approaches that made 2019 a 'banner year' for TB research.
Source: EurekAlert! - Infectious and Emerging Diseases - February 11, 2020 Category: Infectious Diseases Source Type: news
NIH clinical trial of remdesivir to treat COVID-19 begins
(NIH/National Institute of Allergy and Infectious Diseases) A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) has begun at the University of Nebraska Medical Center in Omaha. The trial regulatory sponsor is the National Institute of Allergy and Infectious Diseases. This is the first clinical trial in the US to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in China.
Source: EurekAlert! - Infectious and Emerging Diseases - February 25, 2020 Category: Infectious Diseases Source Type: news
